Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
DPP1 Inhibitor
DPP-1-IN-1 is a potent inhibitor of Cathepsin C (Dipeptidyl peptidase I) with an IC50 of 5.31 nM. It effectively inhibits the activity of Cathepsin C, subsequently affecting Neutrophil elastase in neutrophils. This compound is valuable for research in the field of inflammatory diseases, providing insights into mechanisms of inflammation and potential therapeutic pathways. -
DPP-4 Inhibitor
TAK-100 is a selective, orally active dipeptidyl peptidase IV (DPP-4) inhibitor, exhibiting an IC50 of 5.3 nM. This compound demonstrates minimal inhibitory effects on other dipeptidyl peptidases, highlighting its specificity. TAK-100 is primarily utilized in research focused on diabetes, facilitating the exploration of glucose metabolism and insulin regulation. -
DPP1 Inhibitor
Propyl-GSK-2793660 is an irreversible and covalent inhibitor of Dipeptidyl Peptidase I (DPP1). This compound exhibits significant biological activity in the modulation of DPP1 activity, making it a valuable tool for studying conditions related to bronchiectasis. Its specificity and mechanism of action can facilitate research on the implications of DPP1 inhibition in various biological contexts. -
DPP-4 Inhibitor
Melogliptin is a DPP-4 inhibitor that plays a crucial role in modulating glucose metabolism. By inhibiting the DPP-4 enzyme, Melogliptin enhances incretin levels, leading to improved insulin secretion and reduced glucagon levels. This compound is primarily utilized in research targeting type 2 diabetes and related metabolic disorders, providing insights into potential therapeutic strategies for glucose regulation. -
DPP-4 Inhibitor
MK-0626 is a selective Dipeptidyl Peptidase-4 (DPP-4) inhibitor, exhibiting an IC50 of 6.3 nM. This compound enhances endothelial nitric oxide synthase expression and is effective in promoting neovascularization. MK-0626 demonstrates potential in mitigating hepatic steatosis and pancreatic islet injury. It is particularly relevant in research focused on diabetes and non-alcoholic fatty liver disease. -
DPP Covalent Inhibitor
Sulphostin is a covalent inhibitor targeting dipeptidyl peptidase 4 (DPP4), dipeptidyl peptidase 9 (DPP9), and dipeptidyl peptidase 8 (DPP8) with IC50 values of 79, 1392, and 6930 nM, respectively. By inducing phosphosulfamate modification, Sulphostin irreversibly inhibits these enzyme activities, making it a valuable tool in the study of inflammatory processes and cancer research. Its selective inhibition profile allows for detailed investigation into the roles of DPPs in various biological pathways. -
DPP4 Inhibitor
P32/98 hemifumarate is a potent dipeptidyl peptidase IV (DPP4) inhibitor with a Ki value of 130 nM. It has been shown to enhance glucose tolerance, improve insulin sensitivity, and increase β-cell responsiveness in a fatty Zucker rat model. This compound is valuable for research applications focused on diabetes and metabolic disorders, providing insights into DPP4 inhibition mechanisms and their effects on glucose homeostasis. -
DPP9 Inhibitor
DPP9-IN-1 is a selective inhibitor of dipeptidyl peptidase 9 (DPP9) with an IC50 value of 3 nM, also exhibiting inhibition of DPP8 at 0.6 μM. This compound has been shown to induce concentration-dependent lactate dehydrogenase (LDH) release in THP-1 cells, indicating potential cytotoxic effects. DPP9-IN-1 is useful in research applications related to immune response modulation and study of DPP9-related pathways in cellular processes. -
DPP4 Inhibitor
P32/98 is a potent dipeptidyl peptidase IV (DPP4) inhibitor, exhibiting a Ki value of 130 nM. This compound is notable for its ability to enhance glucose tolerance, improve insulin sensitivity, and increase β-cell responsiveness, specifically in the fatty Zucker rat model. P32/98 is suitable for research applications targeting metabolic disorders and studying glucose homeostasis. -
DPP4 Inhibitor
SGP8 (IAVPGEVA) is a DPP4 inhibitor that demonstrates significant modulation of lipid metabolism, inflammation, and fibrosis. By inhibiting DPP4 activity, SGP8 affects the JNK-c-Jun signaling pathway and shows potential therapeutic applications in the treatment of non-alcoholic steatohepatitis (NASH). This octapeptide, derived from the hydrolysis of soybean 11S globulin, serves as a valuable tool for research in metabolic disorders and related inflammatory conditions. -
DPP-4 Inhibitor
DPP-4-IN-15 is a non-competitive inhibitor of dipeptidyl peptidase-4 (DPP-4), exhibiting an IC50 value of 8.24 μM. This compound effectively modulates the activity of DPP-4, an enzyme involved in glucose metabolism and insulin regulation. DPP-4-IN-15 is primarily utilized in diabetes research, providing insights into the potential therapeutic effects of DPP-4 inhibition on glycemic control and related metabolic disorders. -
DPP-III Inhibitor
Fluostatin A is a potent inhibitor of dipeptidyl peptidase III (DPP-III), demonstrating an IC50 value of 0.44 μg/mL with the substrate arginyl-arginine-2-naphthalene formamide. By modulating DPP-III activity, Fluostatin A plays a significant role in studies related to peptide metabolism and signaling pathways. This compound is suitable for research applications in diabetes, cardiovascular disease, and other metabolic disorders targeting DPP-III enzymatic regulation. -
DPP-IV inhibitor
AMG-222 tosylate is a potent DPP-IV inhibitor, primarily employed in the investigation of type II diabetes. By modulating the activity of the DPP-IV enzyme, AMG-222 tosylate facilitates enhanced insulin secretion and improved glycemic control. This compound is valuable for research aimed at understanding the mechanisms of glucose homeostasis and developing therapeutic approaches for managing diabetes. -
DPP-3 Inhibitor
Fluostatin B is a dipeptidyl peptidase 3 (DPP-3) inhibitor with an IC50 value of 24 µg/mL. As a natural product derived from Streptomyces, this compound exhibits potential biological activity in modulating peptide metabolism. Fluostatin B is relevant for research applications focused on understanding DPP-3's role in various physiological processes and exploring its implications in disease states such as diabetes and cancer. -
DPP-4 Inhibitor
H-Gly-Pro-Hyp-OH acetate functions as a dipeptidyl peptidase 4 (DPP-4) inhibitor, exhibiting an IC50 value of 2.51 mM. This compound has shown promise in the investigation of diabetes-related pathways and therapeutic strategies. Its ability to modulate DPP-4 activity makes it a valuable reagent for research in metabolic disorders and glucose homeostasis. -
DPP4 Inhibitor
HTS13517 is a selective inhibitor of Dipeptidyl Peptidase IV (DPP4), exhibiting an IC50 value of 10.73 μM. This compound is relevant for studies investigating the modulation of glucose metabolism and the regulation of incretin hormones. Its applications include diabetes research and the exploration of therapeutic strategies targeting metabolic disorders. -
DPP4 Inhibitor
Garvagliptin is a selective and orally active dipeptidyl peptidase-4 (DPP4) inhibitor, achieving an IC50 of 2.99 nM against human recombinant DPP IV. Its primary mechanism facilitates the enhancement of incretin levels, thereby exhibiting antihyperglycemic effects. Garvagliptin is widely utilized in diabetes research to explore its potential in glycemic control and metabolic regulation. -
Aldose Reductase Inhibitor
Zopolrestat is a potent inhibitor of aldose reductase (AR) with an IC50 of 3.1 nM. This compound is primarily utilized in research focused on diabetic complications, providing insights into the metabolic pathways involved in diabetes-related disorders. Its application extends to studying the therapeutic potential in mitigating diabetic neuropathy and retinopathy, making it a valuable tool in diabetes research. -
Aldose Reductase Inhibitor
Ganoderic acid C2 is a bioactive triterpenoid that functions as an aldose reductase inhibitor, displaying an IC50 of 43.8 µM. This compound exhibits potential anti-tumor activity along with antihistamine and anti-aging properties. Its cytotoxic effects make Ganoderic acid C2 a valuable reagent for research in fields such as cancer biology and metabolic disorders. -
Aldose Reductase Inhibitor
6-Hydroxyluteolin is a flavonoid identified as an aldose reductase inhibitor. It demonstrates potential antidiabetic activity by reducing the conversion of glucose to sorbitol, thereby mitigating osmotic and oxidative stress in diabetic tissues. This compound is useful in research applications focused on diabetes-related complications and metabolic disorders. -
Aldose Reductase Inhibitor
Zenarestat is a potent and orally active inhibitor of aldose reductase, an enzyme involved in the polyol pathway. This compound demonstrates significant biological activity by improving symptoms of diabetic peripheral neuropathy in preclinical models, specifically in Zucker diabetic fatty rats. Zenarestat may serve as a valuable tool for research into diabetic complications and the modulation of glucose-related metabolic disorders. -
Aldose Reductase Inhibitor
Exisulind is an aldose reductase inhibitor with an IC50 of 367 nM in vitro. As an inactive metabolite of sulindac, it may play a role in mitigating complications associated with type 2 diabetes through its pharmacological effects. This compound is valuable for research focused on metabolic disorders and the management of diabetes-related complications. -
Aldose Reductase Inhibitor
Lidorestat is a potent and selective aldose reductase inhibitor, exhibiting an IC50 of 5 nM. This compound is primarily used in research focused on chronic complications associated with diabetes. It has demonstrated efficacy in enhancing nerve conduction and reducing the formation of cataracts, making it valuable for studies relating to diabetic neuropathy and cataractogenesis. -
Aldose reductase Inhibitor
Ganoderic acid C6 functions as an aldose reductase inhibitor, effectively modulating glucose metabolism. This compound is important for research aimed at understanding diabetic complications and oxidative stress management. Its potential to influence pathways associated with diabetic neuropathy and retinopathy makes it a valuable reagent for investigating therapeutic strategies in metabolic disorders. -
ACE/NEP Inhibitor
Fasidotril is a dual inhibitor of neprilysin and angiotensin-converting enzyme (ACE). It demonstrates significant biological activity in the modulation of blood pressure and fluid balance, making it a valuable tool in hypertension and congestive heart failure (CHF) research. The compound's ability to inhibit both pathways provides insight into the therapeutic potential for cardiovascular disease management. -
ACE/NEP Inhibitor
AD015 is a dual inhibitor of angiotensin-converting enzyme (ACE) and neprilysin (NEP). It exhibits potent inhibitory activity against NEP, with an IC50 of 0.009 µM, and shows strong inhibition of both nephron ACE (nACE) and cardiac ACE (cACE), with IC50 values of 0.019 µM and 0.0008 µM, respectively. This compound is valuable for research in cardiovascular and renal physiology, particularly in studies related to hypertension and heart failure, where modulation of the renin-angiotensin system is critical. -
NEP Inhibitor
Z-13752A is a mercaptopropanoyl amino acid that functions as an inhibitor of neprilysin (NEP) and angiotensin-converting enzyme (ACE) with Ki values of 1.8 nM and 3.2 nM, respectively. This compound has been shown to effectively reduce arterial blood pressure while enhancing coronary blood flow. Z-13752A is valuable for research focused on coronary artery occlusion and related cardiovascular conditions. -
cACE/NEP Inhibitor
AD011 is a dual inhibitor of carboxypeptidase angiotensin-converting enzyme (cACE) and neprilysin (NEP). This compound is derived from the C-domain selective ACE inhibitor lisinopril-tryptophan and demonstrates significant antihypertensive and cardioprotective effects. AD011 is suitable for research applications focused on cardiovascular health and the modulation of renin-angiotensin system pathways. -
cACE/NEP Inhibitor
AD013 is a dual inhibitor of the enzymes cACE (constitutive Angiotensin-Converting Enzyme) and NEP (Neutral Endopeptidase). This compound is derived from a C-domain selective ACE inhibitor and has demonstrated significant potential in providing antihypertensive and cardioprotective effects. AD013 serves as a valuable reagent for research focused on cardiovascular diseases and hypertension therapies. -
Aldose Reductase Inhibitor
Alrestatin is a selective inhibitor of aldose reductase, an enzyme implicated in the development of diabetic complications such as diabetic neuropathy. By inhibiting this enzyme, Alrestatin plays a role in modulating glucose metabolism and reducing oxidative stress. This compound is useful for research focused on diabetes-related pathologies and potential therapeutic interventions. -
Aldose Reductase Inhibitor
Cornoside is a phenolic glycoside that acts as an aldose reductase inhibitor, exhibiting an IC50 of 150 μM against rat lens aldose reductase. This compound is valuable in research focused on diabetic complications and oxidative stress-related conditions. Its ability to modulate aldose reductase activity makes it a significant tool for studying pathways involved in polyol metabolism. -
Aldose Reductase Inhibitor
Mumeose K is an aldose reductase inhibitor with an IC50 value of 27 μM. This compound demonstrates potential anti-diabetic activity and is suitable for research focused on diabetes-related complications. Its mechanism of action may aid in understanding the role of aldose reductase in diabetic pathology, making it a valuable tool for investigative studies in metabolic disorders. -
Aldose Reductase Inhibitor
Asperaldin is a potent inhibitor of aldose reductase, an enzyme involved in the polyol pathway that converts glucose to sorbitol. Isolated from Aspergillus niger CFR-1046, Asperaldin has demonstrated significant biological activity in the modulation of diabetic complications and oxidative stress. This compound serves as a valuable tool for research applications aimed at understanding the role of aldose reductase in various metabolic disorders. -
Aldose Reductase Inhibitor
Ganoderic acid Df is a lanostane-type triterpenoid that selectively inhibits aldose reductase, demonstrating an IC50 value of 22.8 ± 0.6 μM. This compound is derived from the fruiting body of Ganoderma lucidum and exhibits significant potential for research applications related to diabetic complications and oxidative stress. Its ability to modulate aldose reductase activity makes it a valuable tool for studying various metabolic disorders and therapeutic interventions. -
Aldose Reductase Inhibitor
Minalrestat is a potent and orally active inhibitor of aldose reductase. It demonstrated significant biological activity in reducing polyol accumulation, making it a valuable compound in the study of diabetic complications. This reagent is particularly useful for researching the pathway of diabetic macular edema and other conditions linked to hyperglycemia. -
Aldose Reductase Inhibitor
Methosorbinil is an aldose reductase inhibitor known for its efficacy in preventing cataract formation. By inhibiting aldose reductase, it plays a significant role in regulating glucose metabolism and reducing sorbitol accumulation. This compound is primarily utilized in research focused on diabetes-related complications and ocular health. -
Aldose Reductase Inhibitor
Myrciacetin is a flavonoid that functions as an aldose reductase inhibitor, derived from Rhododendron dauricum. It demonstrates significant biological activity, exhibiting an IC50 value of 13 μM against rat lens aldose reductase. This compound is primarily utilized in research related to diabetic complications and oxidative stress, making it a valuable tool in the study of metabolic disorders. -
Aldose Reductase Inhibitor
Dehydroglyasperin D is a selective inhibitor of Aldose Reductase (AR), demonstrating IC50 values of 62.4 μM for rat AR and 176.2 μM for human AR. This compound exhibits significant anti-obesity and antioxidant properties, in addition to its anti-inflammatory effects, which involve the inhibition of COX-2 expression and the MLK3 signaling pathway. Moreover, Dehydroglyasperin D inhibits melanin synthesis, making it relevant for research in metabolic disorders and pigmentation. Isolated from Glycyrrhiza uralensis, this prenylated flavonoid serves as a valuable tool for studying various biological processes. -
Aldose Reductase Inhibitor
Aldose reductase-IN-4 is a selective aldose reductase inhibitor, exhibiting IC50 values of 11.70 μM for aldehyde reductase 1 (ALR1) and 0.98 μM for aldose reductase 2 (ALR2). This compound plays a significant role in modulating the polyol pathway, which is crucial in the context of diabetic complications. Aldose reductase-IN-4 is useful in research applications focusing on diabetes, oxidative stress, and related metabolic disorders. -
Aldose Reductase Inhibitor
Floramanoside D is a flavonol glycoside that functions as an aldose reductase inhibitor, with an IC50 value of 2.2 μM, making it effective in the modulation of glucose metabolism. Additionally, it exhibits antioxidant properties by scavenging 2,2-diphenyl-1-picrylhydrazyl (DPPH), with an SC50 of 12.5 μM. This compound is valuable for research in diabetes-related complications and oxidative stress studies. -
Aldose Reductase Inhibitor
M 16209 is an orally active inhibitor of aldose reductase (AR), a key enzyme in the polyol pathway. This compound demonstrates effective inhibition of AR from multiple sources, with IC50 values of 0.12 μM for rat lens AR, 0.24 μM for bovine lens AR, 4.5 μM for bovine kidney AR, 1.2 μM for canine lens AR, and 9.3 μM for human placental AR. M 16209 is valuable for research into metabolic diseases, particularly diabetes, by influencing the glucose metabolic pathway and potentially mitigating complications associated with hyperglycemia. -
Aldose Reductase Inhibitor
6-Methoxytricin is an aldose reductase inhibitor derived from Artemisia iwayomogi. This flavonoid demonstrates notable biological activity, with IC50 values of 30.29 μM for aldose reductase inhibition and 134.88 μM for advanced glycation end product formation. Due to its mechanism of action, 6-Methoxytricin is being investigated for its potential to mitigate diabetic complications. -
Aldose Reductase Inhibitor.
ADN 138 is an aldose reductase inhibitor that effectively reduces sorbitol levels in diabetic nerves. This compound leads to significant increases in motor nerve conduction velocity (MNCV) and enhances Na+, K+-ATPase activity in nerve tissues. ADN 138 is valuable for research investigating diabetic neuropathy and related complications, providing insights into potential therapeutic strategies for diabetes-induced nerve damage. -
Aldose Reductase Inhibitor
Hydroxyevodiamine is an aldose reductase inhibitor, demonstrated to have an IC50 value of 24.1 μM. This compound plays a significant role in the regulation of glucose metabolism and is relevant in research related to diabetic complications and oxidative stress. Its inhibitory activity against aldose reductase makes it a valuable tool for studying the biochemical pathways associated with hyperglycemia and related pathologies. -
Aldose Reductase Inhibitor
EBPC is a potent and selective inhibitor of aldose reductase, exhibiting an IC50 of 47 nM. This compound effectively modulates the conversion of glucose to sorbitol, thereby offering significant potential in the study of diabetes-related complications. It serves as a useful tool for researchers investigating the roles of aldose reductase in oxidative stress and diabetic neuropathy. -
Aldose Reductase Inhibitor
(Rac)-Fidarestat is a potent inhibitor of aldose reductase, acting to regulate glucose metabolism and prevent the accumulation of sorbitol in cells. This compound is primarily utilized in research focused on diabetic complications, particularly in relation to neuropathy and retinopathy. Its effectiveness in modulating polyol pathway activity makes it a valuable tool for studying therapeutic approaches to manage hyperglycemia-related tissue damage. -
Aldose Reductase Inhibitor
ARI-809 is a potent and selective aldose reductase inhibitor, exhibiting an IC50 of 1 nM. By inhibiting aldose reductase, ARI-809 effectively reduces excessive glucose flux through the polyol pathway, resulting in the normalization of elevated sorbitol and fructose levels in diabetic models. This compound demonstrates significant potential in alleviating complications associated with diabetes, such as sorbitol accumulation in lens tissues and elevated urinary albumin excretion. ARI-809 is suitable for use in diabetes-related research applications. -
Aldose Reductase Inhibitor
Aldose reductase-IN-6 is a competitive inhibitor of aldose reductase (AR) with an IC50 of 3.164 μM and a Ki value of 0.018 μM. This compound demonstrates effective inhibition without cytotoxic effects on healthy cells, making it a valuable tool for investigating the role of aldose reductase in various biological processes. It is particularly relevant in studies related to diabetic complications and oxidative stress. -
Aldose Reductase Inhibitor
SG-210 is a selective aldose reductase (AR) inhibitor exhibiting potency with IC50 values of 9.5 nM and 10 nM for AR from porcine lens and human placenta, respectively. By inhibiting aldose reductase, SG-210 effectively reduces sorbitol accumulation, which is beneficial in mitigating complications associated with diabetes, such as neuropathy and retinopathy, in streptozotocin-induced diabetic models. This compound serves as a valuable tool for research into diabetes-related pathologies and the mechanisms underlying metabolic disorders. -
Aldose Reductase 2 Inhibitor
ALR2-IN-10 is an inhibitor of Aldose Reductase 2, exhibiting a modest inhibition rate of 6% at a concentration of 27 μM. This compound is relevant for research related to diabetic complications, providing insights into the pharmacological modulation of glucose metabolism and related pathways. Suitable for studies exploring the therapeutic potential of targeting aldose reductase in diabetes-related tissue damage.
